Simon Kreutzfeldt
Overview
Explore the profile of Simon Kreutzfeldt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Horak P, Griffith M, Danos A, Pitel B, Madhavan S, Liu X, et al.
Genet Med
. 2022 Feb;
24(5):986-998.
PMID: 35101336
Purpose: Several professional societies have published guidelines for the clinical interpretation of somatic variants, which specifically address diagnostic, prognostic, and therapeutic implications. Although these guidelines for the clinical interpretation of...
12.
Matrood S, Apostolidis L, Schrader J, Krug S, Lahner H, Ramaswamy A, et al.
Front Endocrinol (Lausanne)
. 2021 Oct;
12:709256.
PMID: 34690926
Background And Aims: Neuroendocrine neoplasms (NENs) of the presacral space are an extremely rare disease entity with largely unknown outcome and no established standard of care treatment. Therefore, we wanted...
13.
Horak P, Leichsenring J, Kreutzfeldt S, Kazdal D, Teleanu V, Endris V, et al.
Pathologe
. 2021 Oct;
42(6):602.
PMID: 34605937
No abstract available.
14.
Horak P, Leichsenring J, Goldschmid H, Kreutzfeldt S, Kazdal D, Teleanu V, et al.
Genes Chromosomes Cancer
. 2021 Jul;
61(6):303-313.
PMID: 34331337
Modern concepts in precision cancer medicine are based on increasingly complex genomic analyses and require standardized criteria for the functional evaluation and reporting of detected genomic alterations in order to...
15.
Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hullein J, et al.
Cancer Discov
. 2021 Jun;
11(11):2780-2795.
PMID: 34112699
The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a...
16.
Hlevnjak M, Schulze M, Elgaafary S, Fremd C, Michel L, Beck K, et al.
JCO Precis Oncol
. 2021 May;
5.
PMID: 34036222
Purpose: CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program...
17.
Horak P, Leichsenring J, Kreutzfeldt S, Kazdal D, Teleanu V, Endris V, et al.
Pathologe
. 2021 May;
42(4):369-379.
PMID: 33938987
Increasingly extensive genomic diagnostics in cancer precision medicine require uniform evaluation criteria for the classification of variants with regard to their functional and therapeutic implications. In this review we present...
18.
Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss D, et al.
Nat Commun
. 2021 Jan;
12(1):498.
PMID: 33479225
Sarcomas are malignant soft tissue and bone tumours affecting adults, adolescents and children. They represent a morphologically heterogeneous class of tumours and some entities lack defining histopathological features. Therefore, the...
19.
Hubschmann D, Jopp-Saile L, Andresen C, Kramer S, Gu Z, Heilig C, et al.
Genes Chromosomes Cancer
. 2020 Nov;
60(5):314-331.
PMID: 33222322
Different mutational processes leave characteristic patterns of somatic mutations in the genome that can be identified as mutational signatures. Determining the contributions of mutational signatures to cancer genomes allows not...
20.
Wahjudi L, Bernhardt S, Abnaof K, Horak P, Kreutzfeldt S, Heining C, et al.
Int J Cancer
. 2020 Sep;
148(6):1438-1451.
PMID: 32949162
DNA sequencing and RNA sequencing are increasingly applied in precision oncology, where molecular tumor boards evaluate the actionability of genetic events in individual tumors to guide targeted treatment. To work...